Article Information
History
- May 27, 2022.
Article Versions
- You are currently viewing Version 1 of this article (May 27, 2022 - 20:12).
- Version 2 (November 11, 2022 - 06:25).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- David J. Sullivan, M.D.1,*,
- Daniele Focosi, M.D.2,
- Daniel Hanley, M.D.3,
- Massimo Franchini, M.D.4,
- Jiangda Ou, M.S.3,
- Arturo Casadevall, M.D.1 and
- Nigel Paneth, M.D.5
- 1Johns Hopkins Bloomberg School of Public Health, Department of Molecular Microbiology and Immunology, Baltimore, MD USA
- 2North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy
- 3Johns Hopkins University School of Medicine Department of Neurology, Brain Injury Outcomes Division, Baltimore, MD, USA
- 4Division of Hematology, Carlo Poma Hospital, Mantua, Italy
- 5Departments of Epidemiology & Biostatistics and Pediatrics & Human Development, College of Human Medicine, Michigan State University, East Lansing, MI, USA
- ↵*Corresponding author: David Sullivan, 615 N. Wolfe St Rm W4606, Baltimore MD 21205. Tel 410 502 2522, fax 410 955 0105. E-mail dsulliv7{at}jhmi.edu.
Posted May 27, 2022.
Effective antiviral regimens to reduce COVID-19 hospitalizations: a systematic comparison of randomized controlled trials
